

PATENT

Appl. No. 09/027,205

Second Suppl. Amdt. dated August 5, 2004

Reply to Office Action dated November 5, 2003

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-95. (Cancelled)

Claim 96. (Previously Presented): An *ex vivo* method for downregulating CCR5 expression in a T cell comprising contacting the T cell with a bead comprising an anti-CD28 antibody or a fragment thereof and an anti-CD3 antibody or a fragment thereof; and measuring the level of CCR5 expression in said contacted T cell, wherein the level of CCR5 expression in said contacted T cell is lower than the level of the CCR5 expression in a T cell not contacted with said bead.

Claim 97. (Previously Presented): A method for downregulating CCR5 expression in a T cell, comprising contacting the T cell *in vivo* with a bead comprising an anti-CD28 antibody or a fragment thereof and an anti-CD3 antibody or a fragment thereof; and measuring the level of CCR5 expression in said contacted T cell, wherein the level of CCR5 expression in said contacted T cell is lower than the level of the CCR5 expression in a T cell not contacted with said bead.

Claim 98. (Cancelled)

Claim 99. (Currently Amended): The method of any one of claims ~~95-98~~ 96 or 97, wherein the anti-CD3 antibody is an anti-human CD3 monoclonal antibody.

## PATENT

Appl. No. 09/027,205

Second Suppl. Amdt. dated August 5, 2004

Reply to Office Action dated November 5, 2003

Claim 100. (Currently Amended): The method of any one of claims ~~95-98~~ 96 or 97, wherein the anti-CD28 antibody is an anti-human CD28 monoclonal antibody.

Claim 101. (Currently Amended): The method of any one of claims ~~95-98~~ 96 or 97, wherein the anti-CD3 antibody or fragment thereof and the anti-CD28 antibody or fragment thereof are coupled to the bead via a covalent modification.

Claim 102. (Currently Amended): The method of any one of claims ~~95-98~~ 96 or 97, wherein the anti-CD3 antibody or fragment thereof and the anti-CD28 antibody or fragment thereof are coupled to the bead via an avidin-biotin complex.

Claim 103. (Currently Amended): The method of any one of claims ~~95-98~~ 96 or 97, wherein the anti-CD3 antibody and the anti-CD28 antibody are directly coupled to the bead.

Claim 104. (Currently Amended): The method of any one of claims ~~95-98~~ 96 or 97, wherein the bead is a biodegradable bead.

Claim 105. (Currently Amended): The method of any one of claims ~~95-98~~ 96 or 97, wherein the bead is a magnetic bead.

Claim 106. (Currently Amended): The method of any one of claims ~~95-98~~ 96 or 97, wherein the anti-CD28 antibody or fragment thereof and the anti-CD3 antibody or fragment thereof, are coupled to the same bead.

Claim 107. (Currently Amended): The method of any one of claims ~~95-98~~ 96 or 97, wherein the T cells comprise HIV-infected T cells.